Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Feb;35(2):220–223. doi: 10.1128/aac.35.2.220

Pharmacokinetics and antibacterial efficacy of cefpirome (HR 810) in experimental Escherichia coli and Haemophilus influenzae type b meningitis.

H S Jafari 1, X Sáez-Llorens 1, O Ramilo 1, S L Shelton 1, G H McCracken Jr 1
PMCID: PMC244980  PMID: 2024953

Abstract

Cefpirome (HR 810) is a new cephalosporin related to cefotaxime that has potent bactericidal activity against a broad spectrum of gram-negative and gram-positive organisms. The pharmacokinetics and bacteriological efficacy of cefpirome administered as a single intravenous dose were assessed in rabbits with experimental Haemophilus influenzae type b and Escherichia coli K1 meningitis. The mean penetrations into the cerebrospinal fluid (CSF) in relation to the amount of drug in serum of animals infected with H. influenzae and E. coli were 25 and 54%, respectively. The median CSF bactericidal titers were 1:128 against both organisms at 1 h of uninfected animals, the mean penetration was 4.5%. There was a significant reduction in the concentrations of bacteria in CSFs of both groups of animals treated with cefpirome compared with that in untreated groups. Mortality was also significantly lower in treated animals than it was in untreated animals. Intravenous administration of dexamethasone before the cefpirome dose did not compromise penetration, bactericidal titers, or antibacterial activity of cefpirome in CSF.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bertram M. A., Bruckner D. A., Young L. S. In vitro activity of HR 810, a new cephalosporin. Antimicrob Agents Chemother. 1984 Aug;26(2):277–279. doi: 10.1128/aac.26.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clarke A. M., Zemcov S. J., Wright J. M. HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother. 1985 Mar;15(3):305–310. doi: 10.1093/jac/15.3.305. [DOI] [PubMed] [Google Scholar]
  3. Dacey R. G., Sande M. A. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob Agents Chemother. 1974 Oct;6(4):437–441. doi: 10.1128/aac.6.4.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Feldman W. E. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr. 1976 Apr;88(4 Pt 1):549–552. doi: 10.1016/s0022-3476(76)80003-0. [DOI] [PubMed] [Google Scholar]
  5. Fuchs P. C., Jones R. N., Barry A. L. In vitro antibacterial spectrum of E1040 compared with those of cefpirome and ceftazidime and disk diffusion interpretive criteria for E1040. Antimicrob Agents Chemother. 1990 May;34(5):914–917. doi: 10.1128/aac.34.5.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lebel M. H., Freij B. J., Syrogiannopoulos G. A., Chrane D. F., Hoyt M. J., Stewart S. M., Kennard B. D., Olsen K. D., McCracken G. H., Jr Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med. 1988 Oct 13;319(15):964–971. doi: 10.1056/NEJM198810133191502. [DOI] [PubMed] [Google Scholar]
  7. McCracken G. H., Jr, Lebel M. H. Dexamethasone therapy for bacterial meningitis in infants and children. Am J Dis Child. 1989 Mar;143(3):287–289. doi: 10.1001/archpedi.1989.02150150041013. [DOI] [PubMed] [Google Scholar]
  8. McCracken G. H., Jr, Nelson J. D., Grimm L. Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis. Antimicrob Agents Chemother. 1982 Feb;21(2):262–267. doi: 10.1128/aac.21.2.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mustafa M. M., Ramilo O., Mertsola J., Risser R. C., Beutler B., Hansen E. J., McCracken G. H., Jr Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. J Infect Dis. 1989 Nov;160(5):818–825. doi: 10.1093/infdis/160.5.818. [DOI] [PubMed] [Google Scholar]
  10. Sakata Y., Boccazzi A., McCracken G. H., Jr Pharmacokinetics and bacteriological effect of ceftazidime in experimental Streptococcus pneumoniae, Haemophilus influenzae, and Escherichia coli meningitis. Antimicrob Agents Chemother. 1983 Feb;23(2):213–217. doi: 10.1128/aac.23.2.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schaad U. B., McCracken G. H., Jr, Loock C. A., Thomas M. L. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis. 1981 Feb;143(2):156–163. doi: 10.1093/infdis/143.2.156. [DOI] [PubMed] [Google Scholar]
  12. Seibert G., Klesel N., Limbert M., Schrinner E., Seeger K., Winkler I., Lattrell R., Blumbach J., Dürckheimer W., Fleischmann K. HR 810, a new parenteral cephalosporin with a broad antibacterial spectrum. Arzneimittelforschung. 1983;33(8):1084–1086. doi: 10.1002/chin.198350201. [DOI] [PubMed] [Google Scholar]
  13. Sáez-Llorens X., Ramilo O., Mustafa M. M., Mertsola J., McCracken G. H., Jr Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr. 1990 May;116(5):671–684. doi: 10.1016/s0022-3476(05)82647-2. [DOI] [PubMed] [Google Scholar]
  14. Täuber M. G., Hackbarth C. J., Scott K. G., Rusnak M. G., Sande M. A. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1985 Mar;27(3):340–342. doi: 10.1128/aac.27.3.340. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES